Is magnetic resonance/ultrasound fusion prostate biopsy better than systematic prostate biopsy? an updated meta- and trial sequential analysis
Jian Wu(Sun Yat-sen University), Liping Xie(First Affiliated Hospital Zhejiang University), Yasai Yu(First Affiliated Hospital Zhejiang University), Xiao Wang(Qingdao University), Yi Zhu(Mayo Clinic in Arizona), Ben Liu(Zhejiang Cancer Hospital), Junyuan Wang(Kunming Medical University), Xiangyi Zheng(Tianjin University), Bo Xie(Sun Yat-sen University), Alin Ji(Zhejiang Provincial People's Hospital)
Cited by 19
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276